3.390EUR-0.12%Mkt Cap: 992.33M EURP/E: —Last update: 2026-05-14
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherap…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Valuation
P/E (Trailing)—
P/E (Forward)-39.90
PEG—
P/B5.62
P/S173.00
EV/EBITDA-4.66
EV/Revenue134.03
EPS (TTM)-0.77
EPS (Forward)-0.08
Cash Flow & Leverage
FCF Yield-8.79%
FCF Margin-1520.33%
Operating CF-121.18M EUR
CapEx (TTM)538.00K EUR
Net Debt/EBITDA1.35
Net Debt-223.10M EUR
Technical
SMA 503.548 (-4.4%)
SMA 2002.902 (+16.8%)
Beta-0.24
S&P 52W Chg24.23%
Avg Vol (30d)902.63K
Avg Vol (10d)933.96K
Technical Indicators
RSI (14)45.1
MACD-0.0395
MACD Signal-0.0349
MACD Hist.-0.0046
BB Upper3.665 EUR
BB Middle3.469 EUR
BB Lower3.273 EUR
BB Width11.28%
ATR (14)0.1799 EUR
Vol Ratio (20d)0.96x
52W Range
1.30465% of range4.500
52W High4.500 EUR
52W Low1.304 EUR
Profitability
Gross Margin100.00%
EBITDA Margin0.00%
Profit Margin0.00%
Oper. Margin-5311.11%
ROE-87.07%
ROA-62.87%
Revenue Growth12.50%
Earnings Growth—
Balance Sheet
Debt/Equity0.05
Current Ratio4.76
Quick Ratio4.72
Book Value/Sh0.5964 EUR
Cash/Share0.7750 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 EUR
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Ownership
Shares Out.295.91M
Float180.76M
Insiders0.10%
Institutions54.68%
Analyst Consensus
Rating2.3 (Buy)
Target (Mean)3.800 EUR
Target Range1.000 EUR – 5.500 EUR
# Analysts3
Company
Market Cap992.33M EUR
Enterprise Value768.80M EUR
Revenue (TTM)5.74M EUR
Gross Profit5.74M EUR
Net Income (TTM)-146.95M EUR
Revenue/Share0.0260 EUR
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees161
Last Price3.390 EUR
CountryFR
SectorHealthcare
IndustryBiotechnology
ISIN—